3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Breast Neoplasms
25
Neoplasms
12
Prostatic Neoplasms
9
Multiple Myeloma
9
Neoplasm Metastasis
7
Giant Cell Tumor of Bone
7
Osteoporosis
4
Fractures, Bone
4
Recurrence
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Bone Diseases, Metabolic
3
Bone Diseases
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Bone Neoplasms
2
Bone Metastases
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Interventions
avapritinib
4
midostaurin
3
masitinib
2
Imatinib Mesylate
2
sarilumab
1
ripretinib
1
obatoclax
1
nilotinib
1
ibrutinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
denileukin diftitox
1
auricularum
1
Thalidomide
1
Ranitidine
1
Ibuprofen
1
Everolimus
1
Diphenhydramine
1
Dexamethasone
1
Denosumab
1
Dasatinib
1
Cladribine
1
Calcium Dobesilate
1
Brentuximab Vedotin
1
Azacitidine
1
Acetaminophen
1
AK002
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mastocytosis, Systemic
×
Denosumab
×
Clear all
NCT03401060
2026-03-31
DenosuMast
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
24 enrolled